RT Conference Proceedings
T1 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)
A1 Neven, P.
A1 Fasching, P. A.
A1 Chia, S.
A1 Jerusalem, G.
A1 De laurentiis, M.
A1 Im, S. -A.
A1 Petrakova, K.
A1 Bianchi, G. V.
A1 Martin Jimenez, M.
A1 Nusch, A.
A1 Sonke, G. S.
A1 de la Cruz Merino, L.
A1 Beck, J. T.
A1 Zarate, J. P.
A1 Wang, Y.
A1 Chakravartty, A.
A1 Wang, C.
A1 Slamon, D.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/21910
UL http://hdl.handle.net/10668/21910
LA en
DS RISalud
RD Apr 8, 2025